First page for those that can't see it yet, basically it puts us 1 step closer to deal with Sarepta Therapeutics
Headlines
PYC achieves major milestones towards the commercialisation of its delivery technology by:
1) Entering a new strategic partnership with the Lions Eye Institute – leading global experts in
the development of drugs for eye diseases;
2) Appointing Professor Sue Fletcher, industry leading expert in the design and development
of precision medicines, as our Chief of Research and Development on a part-time basis;
and
3) Selecting a lead drug candidate for immediate progression to clinical development - a
treatment for the leading cause of childhood blindness – a $1bn p.a. target market with
no existing treatment options – our lead drug candidate has already demonstrated
preliminary evidence of the ability to reverse this disease process in human cells (see
Figure 1 - below).
The combined impact of these developments means that:
i) PYC now has the ability to independently take drugs to market through its commercial
collaboration with the Lions Eye Institute and the appointment of Professor Fletcher;
ii) PYC has advanced from ‘platform only’ to ‘platform and product’. Previously PYC has
been advancing its cell penetrating peptide technology as a platform to deliver drugs.
Now it will be combining that technology with drugs to internally develop a new class
of therapies to cure blinding diseases of the eye;
iii) PYC will continue to commercialise its platform delivery technology either by third party
licensing arrangements or internally through additional drug development programs.
In short, these developments make PYC a drug development company whilst still retaining its core
drug delivery technology for simultaneous exploitation.
- Forums
- ASX - By Stock
- PYC
- Ann: Strategic Partnership and Lead Program
Ann: Strategic Partnership and Lead Program, page-3
-
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
|
|||||
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $559.9M |
Open | High | Low | Value | Volume |
12.5¢ | 12.5¢ | 12.0¢ | $185.3K | 1.515M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 166662 | 12.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.5¢ | 39575 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 166662 | 0.120 |
9 | 834833 | 0.115 |
11 | 941370 | 0.110 |
17 | 1373823 | 0.105 |
25 | 1451907 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 25000 | 2 |
0.130 | 130000 | 2 |
0.135 | 468000 | 3 |
0.140 | 1524545 | 4 |
0.145 | 756800 | 3 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online